Moxetumomab Pasudotox
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Hairy Cell Leukemia
Conditions
Relapsed/Refractory Hairy Cell Leukemia
Trial Timeline
โ โ โ
NCT ID
NCT03501615About Moxetumomab Pasudotox
Moxetumomab Pasudotox is a pre-clinical stage product being developed by AstraZeneca for Relapsed/Refractory Hairy Cell Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03501615. Target conditions include Relapsed/Refractory Hairy Cell Leukemia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03501615 | Pre-clinical | Completed |
Competing Products
20 competing products in Relapsed/Refractory Hairy Cell Leukemia